iBio, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-04. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
Effective July 31, 2026, Molly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. (the "Company").
Appointed: Elizabeth Stoner, Director, effective 2026-05-07
On May 7, 2026, the Board of Directors (the "Board") of iBio, Inc. (the "Company"), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026, and to serve until the Company's 2028 annual meeting of stockholders, at which time her term of office shall expire and a Class II director shall be elected for a full term of three years, or until her re-election or earlier resignation or removal.
Departing: Evert Schimmelpennink, Director
On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.
Find people with the same kind of experience as the Director at iBio, Inc., with the record behind each one.
Find candidates like Director at iBio, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time iBio, Inc. is in the news or changes leadership.
Get an alert when iBio, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for iBio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.